US Patent

US11752154 — Pharmaceutical compositions comprising sepiapterin and uses thereof

Method of Use · Assigned to PTC Therapeutics MP Inc · Expires 2038-09-04 · 12y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pharmaceutical compositions containing sepiapterin and methods for treating tetrahydrobiopterin-related disorders, such as tetrahydrobiopterin deficiency or phenylketonuria.

USPTO Abstract

The present invention features pharmaceutical compositions including sepiapterin, or a pharmaceutically acceptable salt and/or co-crystal thereof, and methods for the treatment of tetrahydrobiopterin-related disorders (e.g., tetrahydrobiopterin deficiency or phenylketonuria) with such compositions.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4251 — Sephience
U-4251 — Sephience

Patent Metadata

Patent number
US11752154
Jurisdiction
US
Classification
Method of Use
Expires
2038-09-04
Drug substance claim
No
Drug product claim
Yes
Assignee
PTC Therapeutics MP Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.